Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in
children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic
pathway gliomas.
This study will test the early and late toxicities of selumetinib when it is given in this
intermittent schedule (in 5 out of 7 days) and will also test the effectiveness of the drug
in reducing the size of plexiform neurofibromas and optic pathway gliomas in children with
NF1. It will also test the effectiveness of the drug in improving the participants function
in day to day life.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Great Ormond Street Hospital for Children NHS Foundation Trust